Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Gastric Cancer

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Gastric Cancer

5 stories · every one Fact-Checked
Scientific illustration of a CLDN18.2-targeted antibody-drug conjugate delivering a cytotoxic payload to gastric cancer cellsClinical TrialsTakeda’s Arcotatug Tavatecan Deliver Dual Survival Benefits in G-HOPE-001 TrialTakeda’s investigational CLDN18.2-targeted ADC arcotatug tavatecan improved overall survival to 10.2 months and progression-free survival to 7.1 months in the Phase 3 G-HOPE-001 study, supporting a planned regulatory…23 Oct 2026 · 4 min read
Fact-Checked
Evorpacept CD47 blockade with trastuzumab-based therapy in HER2-positive gastric cancerClinical TrialsEvorpacept Shows Stronger Responses in HER2+ Gastric CancerALX Oncology’s Phase 2 ASPEN-06 study showed that evorpacept plus trastuzumab, ramucirumab and paclitaxel improved response rates in previously treated HER2-positive gastric and GEJ cancer, with the highest…28 Sep 2026 · 3 min read
Fact-Checked
Durvalumab plus FLOT chemotherapy improves overall survival in resectable gastric and gastroesophageal junction adenocarcinomaClinical TrialsFinal MATTERHORN Analysis Confirms Overall Survival Benefit With Durvalumab Plus FLOT in Resectable Gastric CancerFinal MATTERHORN results show that adding durvalumab to perioperative FLOT chemotherapy significantly improves overall survival in resectable gastric and gastroesophageal junction adenocarcinoma, with higher pathological response rates and…11 Sep 2026 · 3 min read
Fact-Checked
CMG901 (sonesitatug vedotin/AZD0901) demonstrated a significant overall survival benefit in the global Phase III CLARITY-Gastric01 trial for patients with CLDN18.2-positive advanced gastric cancer.Clinical TrialsSonesitatug Vedotin Improves Survival in Phase III Gastric Cancer TrialAstraZeneca’s investigational CLDN18.2-targeted antibody-drug conjugate, sonesitatug vedotin (Sone-Ve), significantly improved overall survival in the Phase III CLARITY-Gastric01 trial for previously treated advanced gastric, gastroesophageal junction, and esophageal adenocarcinomas.…27 Jul 2026 · 4 min read
Fact-Checked
Gemini_Generated_Image_cj7ex8cj7ex8cj7eClinical TrialsInnovent Files China NDA for Arcotatug Tavatecan in Advanced Gastric CancerInnovent Biologics has submitted a New Drug Application in China for arcotatug tavatecan (IBI343; TAK‑921) following positive Phase 3 G‑HOPE‑001 results in CLDN18.2‑positive gastric and gastroesophageal junction adenocarcinoma.…4 Jun 2026 · 3 min read
Fact-Checked
Page 1 of 1